Back to catalogue
№ 204 27 filings · 2021-05-19 → 2026-06-03

IMAGING BIOMETRICS LIMITED

IBAI
Health Care Share price 0.73p Market cap £1.81m Overall fit 180 /1000

Weak AI-receiver alignment (genuine medical-imaging software, not a picks-and-shovels AI beneficiary despite the former 'IQ-AI' name), real operating leverage but at sub-commercial scale, fair-not-cheap valuation, and poor downside protection (£113k cash, recurring dilution, going-concern fragility).

Fair value range 0p–1p Mid case · £1.75m
Absolute upside -3.5% vs current market cap
Conviction 2/5 confidence in fair call
Supports the call
  • Clean audited IFRS disclosure with clear segment splits
  • Simple two-subsidiary structure with traceable unit economics
  • Software segment profitability is demonstrable, not aspirational
Limits the call
  • Micro-cap with thin liquidity; near-certain further dilution clouds per-share value
  • Multi-year pattern of management profitability timelines slipping
Methodology

Blended EV/revenue (1.5-3x) and normalised earnings sanity check

In one line · bull case

Genuinely high-margin neuro-oncology software franchise with credible regulatory tailwinds (ARIA monitoring, anti-animal-testing) and a 2026 cost reset that could finally tip the group into profit.

In one line · biggest risk

Near-zero cash buffer (£113k) plus a five-year track record of dilutive placings at falling strike prices makes further shareholder dilution essentially certain before any operational thesis can play out.

Drivers
AI beneficiary 25 /100
Uses AI techniques in segmentation/contrast simulation but is not a meaningful AI infrastructure receiver; renamed away from 'IQ-AI' branding in 2025.
Operating leverage 70 /100
94% group gross margin and a small fixed-cost base mean each incremental £100k software revenue drops ~£90k to operating profit — high in theory.
Earnings vs expectations 30 /100
Revenue targets broadly met at low end; profitability targets repeatedly pushed out by 12 months across 2022-2025.
Growth momentum 35 /100
FY25 revenue +5% YoY; H1 2025 was -11% YoY; growth has been incremental rather than the 'step-change' repeatedly forecast.
Moat 25 /100
Some FDA-cleared IP and exclusive partnerships, but adoption has been slow and competitors offer overlapping automated solutions.
Earnings quality 30 /100
Repeated intangible impairments (Stone Checker, GaM Phase 1), prior-period restatement in 2024 accounts, capitalised dev costs require judgement.
Management quality 25 /100
CEO sold 45.7m personal shares to related party Braveheart at 1.1p in Oct 2024 ahead of further dilutive placing; perpetual promises of profitability not delivered.
Cyclicality 25 /100
Healthcare diagnostic software and pre-clinical research tools are largely defensive end markets.
Leverage 30 /100
No bank debt but £170k convertible loan, £606k payables vs £113k cash; net current liabilities of £271k.
Value-trap signals · 8
  • Repeated equity placings at successively lower prices (5p 2021 -> 1p 2025)
  • Cumulative operating losses ~£1.9m across 2021-2025 against modest revenue growth
  • Recurring intangible impairments (Stone Checker fully impaired; £241k GaM write-down in 2025)
  • Going-concern flag in every annual report reviewed
  • CEO disposed of large personal stake to related party then further dilution followed
  • High related-party concentration (Truetide owns 86% of acquired Kirkstall and 29% of IBAI)
  • Profitability promised for at least four consecutive years and not yet delivered
  • Prior-period restatement of 2022 accounts disclosed in 2024 annual report

Imaging Biometrics Limited (IBAI) — Research Note

Executive summary

Imaging Biometrics is a sub-£2m UK-listed Jersey micro-cap that develops quantitative neuro-oncology MRI software (Imaging Biometrics LLC, acquired 2018) and, since October 2025, operates a fledgling organ-on-a-chip business (Kirkstall). Across the five-year period covered by the filings, revenue has crept from £521k (2021) to £788k (2025), and the Group has been consistently loss-making with repeated equity raises at declining strike prices and an intangible impairment cycle (Stone Checker, then GaM Phase 1 costs). The single most important point for valuation is that this is a perpetually cash-constrained sub-scale platform whose recurring promise of imminent profitability has not yet been delivered, while equity dilution and going-concern fragility cap intrinsic value at low millions.

Fair value estimate

  • Fair value range: 0.4p – 1.0p per share, implying a market cap range of £1.0m – £2.5m.
  • Methodology: blended EV/revenue and forward-earnings sanity check. The medical-software segment delivered £620k revenue, 97% gross margin and £279k operating profit in 2025 2026-04-30 annual report, but is currently consumed by ~£485k of holding-company costs. Applying 1.5x–3.0x 2025 group revenue (£788k) gives £1.2m–£2.4m; a normalised earnings approach (assuming holding costs come down per management guidance, contributing perhaps £50k–£150k group operating profit on a clean run-rate) at 10–15x gives £0.5m–£2.2m. Both methodologies converge in the £1.0m–£2.5m band.
  • Vs current £1.7m market cap: midpoint fair value (~£1.75m / 0.7p) sits at the current share price. Implied upside/downside: roughly 0% at the midpoint (range −41% to +47%).
  • Caveat: the filings disclose net cash of just £113k against £606k current liabilities and net current liabilities of £271k at 31 Dec 2025 2026-04-30 annual report, so any fair-value estimate should be discounted for the high probability of further dilution.

Sector context

  • Sector: Health Care / Health Care Equipment & Services — specifically clinical decision-support software and pre-clinical research tools. Confirmed.
  • Quality / growth / leverage profile: well below typical Health Care peers. Most quoted health-tech and medical-software peers run on materially larger revenue bases with cleaner balance sheets; IBAI is at a sub-commercial scale, with a persistent loss-making history, repeated impairments, and going-concern footnote sensitivity each year.
  • Listed peers (obvious analogues): Polarean Imaging (LON: POLX, imaging diagnostics, also sub-scale); Feedback plc (LON: FDBK, medical imaging software, similar micro-cap profile); larger reference points include Brainomix (private) and the imaging segments of GE HealthCare / Bayer (its current distribution partners).

Investment thesis (3 bullets)

  • The core neuro-oncology software franchise is genuinely high-margin and profitable on a segment basis. The 2025 medical-software segment generated £620k revenue at ~98% gross margin and £279k operating profit, with global distribution now via GE HealthCare (extended to QSMetric in Dec 2025) 2026-06-03 AGM update; 2026-04-30 annual report.
  • Two secular tailwinds are credible: (i) FDA-mandated ARIA monitoring for anti-amyloid Alzheimer's therapies creates a real wedge for QSMetric, and (ii) Kirkstall's Quasi-Vivo® platform addresses the regulatory shift away from animal testing (FDA Modernization Act 2.0; UK £75m Strategic Roadmap), with Kirkstall delivering 77% YoY growth in 2025 2026-04-30 annual report.
  • Cost reset has been executed. Director fees and overheads were materially cut for 2026; the strategic review in Feb 2026 prioritises core neuroimaging software, and the Phase 1 GaM cash-burn has now been closed 2026-04-30 annual report.

Key risks (3 bullets)

  • Going-concern fragility and certain dilution. Cash of £113k vs net current liabilities of £271k at 31 Dec 2025; share count has risen from ~190m (2023) to 247m (2025), with a £170k convertible loan note and 33.2m unexercised options outstanding 2026-04-30 annual report. The pattern of small dilutive placings at successively lower prices (£0.015 in Feb 2024; £0.01 in Mar 2025) is the base case for the next 12 months.
  • CEO sold a large personal stake to a related party at 1.1p in October 2024 — Trevor Brown disposed of 45.7m shares plus 19.7m via family entity to Braveheart Investment Group, of which he is also CEO, just months before a further 1p placing 2024-10-11 Braveheart acquisition RNS. Related-party concentration is unusually high (Truetide plc owns 86% of Kirkstall and 29.35% of IBAI 2026-04-30 annual report).
  • "Year of revenue acceleration" has been promised since at least 2022 and has not arrived in scale. H1 2025 revenue was down 11% YoY 2025-08-13 half-year report; the 2024 annual report's "modest loss this year, break even or profit next year" forecast was missed (2025 loss of £401k vs £327k in 2024) 2025-04-25 annual report; 2026-04-30 annual report.

Operating leverage

On paper, IBAI exhibits the high-fixed-cost structure that should produce strong operating leverage: 2025 group gross margin was 94% (£737k gross profit on £788k revenue), with £894k of admin expenses driving the £399k operating loss 2026-04-30 annual report. The medical-software segment alone produced a £279k operating profit at 98% gross margin. The fixed-cost base is small in absolute terms (~£800k–£900k administrative) but very large relative to revenue, so each incremental £100k of software revenue should drop ~£90k+ to operating profit. A 10–20% upside surprise on group revenue (£80k–£160k) would, in theory, swing the group from £400k loss to roughly breakeven. The constraint is not operating leverage — it is the persistent gap between management's revenue trajectory and what has been delivered, and the fact that even at 2025 revenue levels the model still loses money once holding costs are added in 2026-04-30 annual report. The 2026 cost reset is the most credible operational lever the Group has yet pulled.

Value-trap signals

  • Five-year revenue CAGR of ~10% but cumulative operating losses ~£1.9m across 2021–2025.
  • Successive equity placings at declining prices (5p in 2021 → 1.5p in 2024 → 1p in 2025).
  • Repeated intangible impairments (Stone Checker fully written off; £241k GaM impairment in 2025).
  • Recurring annual promise of imminent profitability not yet delivered.
  • High insider concentration with related-party transactions (Truetide / Braveheart / Kirkstall vendor overlap).
  • £23.5m accumulated retained losses against £2.5m share capital — a long, expensive history of capital consumption.
  • Going-concern note flagged in every annual report reviewed.
  • Auditor changed and the 2024 annual report was restated for prior-period goodwill / payables errors 2025-04-25 annual report Note 23.

Earnings vs. expectations

  • 2023 full-year (vs Aug 2023 H1 commentary): Management forecast a "step-change starting in the 2nd half of 2023" — actual 2023 revenue grew 17% (£609k vs £536k), modest but missing the "step-change" framing — miss vs narrative.
  • 2024 full-year (vs Nov 2024 trading update guidance of US$900k–1m): Delivered $959k (~£750k) — met.
  • 2025 full-year (vs 2024 outlook of "modest loss…break even or profit next year"): Revenue £788k (+5%), loss widened to £401k — missed the profitability target.
  • 2025 H1: Revenue £394k, -11% YoY — miss.
  • Pattern: revenue growth has been broadly delivered at the low end; profitability targets have been repeatedly pushed out by 12 months. More misses than meets vs management aspiration.

Conviction

Conviction: 2 — low.

  • Anchored by: clean small-balance-sheet disclosure (full IFRS audited accounts, segment splits), and the simplicity of the business (two small subsidiaries with traceable economics).
  • Limited by: (i) micro-cap with sub-£800k revenue makes any forward forecast a wide range; (ii) the value depends heavily on the 2026 cost reset and Kirkstall scaling — both unproven; (iii) certain further dilution makes per-share fair value highly sensitive to the next raise's price; (iv) consistent pattern of management's profitability timeline slipping reduces confidence that 2026 will be different from 2024 or 2025.
Filings consulted · 28

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-06-03Result OF Agm2026-06-03_9599974_result-of-agm.md0.30
  2. 2026-06-03Agm Statement And Business Update2026-06-03_9598337_agm-statement-and-business-update.md0.40
  3. 2026-04-30Annual Report For The Year Ended 31 December 20252026-04-30_9547557_annual-report-for-the-year-ended-31-december-2025.md0.95
  4. 2025-08-13Half Year Report2025-08-13_9050287_half-year-report.md0.77
  5. 2025-05-27Change OF Name2025-05-27_8896636_change-of-name.md0.39
  6. 2025-05-22Result OF Agm2025-05-22_8893193_result-of-agm.md0.20
  7. 2025-04-29Notice OF Agm2025-04-29_8851928_notice-of-agm.md0.20
  8. 2025-04-25Publication OF Annual Report2025-04-25_8847458_publication-of-annual-report.md0.62
  9. 2025-03-18Placing TO Raise 250 0002025-03-18_8784818_placing-to-raise-250-000.md0.46
  10. 2024-11-05New Patent Application And Trading Update2024-11-05_8529282_new-patent-application-and-trading-update.md0.55
  11. 2024-10-11Acquisition OF Interest BY Braveheart2024-10-11_8481078_acquisition-of-interest-by-braveheart.md0.49
  12. 2024-08-13Half Year Report2024-08-13_8364770_half-year-report.md0.58
  13. 2024-05-29Result OF Agm2024-05-29_8229240_result-of-agm.md0.14
  14. 2024-04-29Publication OF Annual Report2024-04-29_8162704_publication-of-annual-report.md0.43
  15. 2024-02-22Placing And Broker Option2024-02-22_8050067_placing-and-broker-option.md0.32
  16. 2023-08-17Half Year Report2023-08-17_7700715_half-year-report.md0.41
  17. 2023-05-23Result OF Agm2023-05-23_7539422_result-of-agm.md0.07
  18. 2023-05-23Agm Statement2023-05-23_7538055_agm-statement.md0.10
  19. 2023-05-03Notice OF Agm2023-05-03_7511469_notice-of-agm.md0.07
  20. 2023-04-26Final Results2023-04-26_4411_final-results.md0.25
  21. 2022-08-16Half Year Report2022-08-16_7126741_half-year-report.md0.23
  22. 2022-05-31Submission OF Fda 510 K Application For IB Zero G2022-05-31_7075106_submission-of-fda-510-k-application-for-ib-zero-g.md0.24
  23. 2022-05-30Result OF Agm2022-05-30_7073682_result-of-agm.md0.07
  24. 2022-05-05Notice OF Agm2022-05-05_7194602_notice-of-agm.md0.07
  25. 2022-04-28Final Results2022-04-28_7089746_final-results.md0.25
  26. 2021-10-07Placing2021-10-07_6714288_placing.md0.17
  27. 2021-08-27Half Yearly Report2021-08-27_6692997_half-yearly-report.md0.23
  28. 2021-05-19Result OF Agm2021-05-19_6434752_result-of-agm.md0.03

This research note was authored by a large language model after reading 27 regulatory filings published between 2021-05-19 and 2026-06-03. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.